TUCSON, Ariz., Feb. 18, 2020 /PRNewswire/ -- Accelerate
Diagnostics, Inc. announced today that management will host a
conference call on Thursday, February 27,
2020 at 4:30 p.m. Eastern Time
to review 2019 fourth quarter and full-year financial results.
To listen to the audio webcast online, visit ir.axdx.com. A
replay of the audio webcast will be available until May 19, 2020.
To listen by phone, dial +1.877.883.0383 and enter the
conference ID: 2860141
International participants may dial +1.412.902.6506. Please dial
in 10-15 minutes prior to the start of the conference. A replay of
the call will be available by telephone at +1.877.344.7529 (U.S.)
or +1.412.317.0088 (international) using the replay code 10138283
until May 19, 2020.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro
diagnostics company dedicated to providing solutions for the global
challenges of antibiotic resistance and sepsis. The Accelerate
Pheno® system and Accelerate PhenoTest® BC kit combine several
technologies aimed at reducing the time clinicians must wait to
determine the most optimal antibiotic therapy for serious
infections. The FDA-cleared system and kit fully automate sample
preparation steps, enabling phenotypic antibiotic susceptibility
results in about 7 hours directly from positive blood cultures.
Recent external studies indicate the solution offers results 1 to 2
days faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual
patient's infection, days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENOTEST" and diamond shaped logos and marks are
registered trademarks of Accelerate Diagnostics, Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accelerate-diagnostics-schedules-call-to-review-2019-fourth-quarter-and-full-year-results-301006877.html
SOURCE Accelerate Diagnostics, Inc.